Literature DB >> 8866739

Psychobiologic correlates of treatment response in schizophrenia.

J A Lieberman1, J M Alvir, A Koreen, S Geisler, M Chakos, B Sheitman, M Woerner.   

Abstract

In studies conducted on largely treatment naive patients in their first episode of psychosis, we have found that treatment outcome is quite good and that most patients recover or at least achieve a substantial degree of symptom remission. However, over the course of their illness and in the context of subsequent psychotic episodes, they may experience some decrease in their treatment response from illness progression. In addition, the heterogeneity of treatment outcome is associated with specific clinical (gender, primary negative symptoms of the deficit state, duration of psychosis) and biological variables (pHVA, ventricular volume). It is unclear whether these variables represent aspects of discrete subtypes of schizophrenia or dimensional measures of pathology within the broad context of a unitary disease entity.

Entities:  

Mesh:

Year:  1996        PMID: 8866739     DOI: 10.1016/0893-133X(95)00200-W

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  37 in total

1.  Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Authors:  K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia.

Authors:  P M Thompson; C Vidal; J N Giedd; P Gochman; J Blumenthal; R Nicolson; A W Toga; J L Rapoport
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 3.  Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation.

Authors:  Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum
Journal:  Schizophr Res       Date:  2012-04-13       Impact factor: 4.939

4.  Anosognosia in schizophrenia: hidden in plain sight.

Authors:  Douglas S Lehrer; Jennifer Lorenz
Journal:  Innov Clin Neurosci       Date:  2014-05

Review 5.  Very poor outcome schizophrenia: clinical and neuroimaging aspects.

Authors:  Serge A Mitelman; Monte S Buchsbaum
Journal:  Int Rev Psychiatry       Date:  2007-08

6.  The revolving door of mental, neurological, and substance use disorders re-hospitalization in rural KwaZulu-Natal Province, South Africa.

Authors:  Andrew Tomita; Yoshan Moodley
Journal:  Afr Health Sci       Date:  2016-09       Impact factor: 0.927

7.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

Review 8.  Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm.

Authors:  Chen-Chung Liu; Hiroyoshi Takeuchi
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

9.  Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.

Authors:  Eric Y H Chen; Christy L M Hui; May M L Lam; Cindy P Y Chiu; C W Law; Dicky W S Chung; Steve Tso; Edwin P F Pang; K T Chan; Y C Wong; Flora Y M Mo; Kathy P M Chan; T J Yao; S F Hung; William G Honer
Journal:  BMJ       Date:  2010-08-19

10.  Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia.

Authors:  Jing-Ying Huang; Chih-Min Liu; Tzung-Jeng Hwang; Yu-Jen Chen; Yung-Chin Hsu; Hai-Gwo Hwu; Yi-Tin Lin; Ming-Hsien Hsieh; Chen-Chung Liu; Yi-Ling Chien; Wen-Yih Isaac Tseng
Journal:  Hum Brain Mapp       Date:  2018-01-28       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.